Immunoassays to study prevalence of antibody against GB virus C in blood donors

Lou, Sheng C.; Qiu, Xiaoxing; Tegtmeier, Gary E.; Leitza, Sandra; Brackett, John M.; Cousineau, Kristen L.; Varma, Amit H.; Seballos, Heidi; Kundu, Sudipta; Kuemmerlea, Steve; Hunt, Jeffrey C.

doi:10.1016/s0166-0934(97)00102-x

Cited by 20 publications

(9 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This test is based on a protein expressed in CHO cells transfected with a plasmid coding for a truncated GBV-C E2 protein. 14 Serological Parameters and Definition of Patient Groups. Serological parameters including antibodies against hepatitis C virus (anti-HCV), hepatitis B suface antigen (HBsAg), and antibodies against hepatitis D virus (anti-HDV) were determined by commercial tests from Abbott Laboratories.…”

Section: Patientsmentioning

confidence: 99%

Antibodies against the GB virus C envelope 2 protein before liver transplantation protect against GB virus Cde novo infection

et al. 1998

Self Cite

View full text Add to dashboard Cite

GB virus C (GBV-C) is a newly discovered RNA virus related to the Flaviviridae family. Although GBV-C is not yet associated with any cause of liver disease, a humoral immune response against the GBV-C envelope 2 (E2) protein has been observed. Therefore, we studied the prevalence and clinical relevance of GBV-C RNA and anti-E2 antibodies in patients undergoing orthotopic liver transplantation (OLT). In addition, we tested whether the prevalence of anti-E2 antibodies may protect against GBV-C infection. Of the 182 liver recipients included in this study, 117 of these were evaluated for GBV-C recurrence or de novo infection. GBV-C RNA was detected in sera or plasma using single-tube, reverse-transcriptase polymerase chain reaction, and anti-E2 antibody was detected by enzyme immunoassay (EIA). Cumulative patient and graft survival was tested by using Kaplan-Meier analysis. The independence of prognostic values was assessed by using Cox regression analysis. Before OLT, GBV-C RNA and anti-E2 were detected in 4.0% to 28.6% and 10.0% to 68.8%, respectively, of patients suffering from different forms of chronic liver diseases. GBV-C reinfection after OLT was determined in 85.7%. Of the patients without evidence of exposure to GBV-C before OLT, 30 of 65 (46.2%) became GBV-C RNA positive after OLT. None of the 38 patients who were anti-E2 antibody positive before OLT became GBV-C RNA positive after OLT. Neither patient nor graft survival was significantly affected by the presence of either GBV-C RNA or anti-E2 antibody before OLT. Our data indicate that 1) GBV-C RNA positive patients have a high risk of reinfection after OLT, and 2) the presence of anti-E2 antibodies before OLT is associated with an absence of GBV-C infection after OLT, which may indicate a protective role of anti-E2 antibodies. (HEPATOLOGY 1998;28:379-384.)

show abstract

Section: Patientsmentioning

confidence: 99%

Antibodies against the GB virus C envelope 2 protein before liver transplantation protect against GB virus Cde novo infection

et al. 1998

Self Cite

View full text Add to dashboard Cite

show abstract

“…This prevalence does not vary significantly from the seroprevalence observed among healthy blood donors [Feucht et al, 1997b;Lou et al, 1997]. However, patients on maintenance hemodialysis are known to have impaired immune system [Goldblum and Reed, 1980].…”

Section: Discussionmentioning

confidence: 71%

GB virus C/hepatitis G virus infection in hemodialysis patients: Determination of seroprevalence by a four-antigen recombinant immunoblot assay

et al. 1999

View full text Add to dashboard Cite

GB Virus C/Hepatitis G Virus (GBV-C/HGV) was identified recently and only two assays, consisting of a single recombinant protein, have been described for determination of the seroprevalence of this virus. An immunoblot assay was devised, which contains four recombinant GBV-C/HGV proteins. In this study, serum samples from 154 patients on maintenance hemodialysis were examined to assess the rate of seroreactivity against GBV-C/HGV. All sera were tested for the presence of antibodies by an in-house recombinant immunoblot assay, for GBV-C/HGV viremia by RT-PCR, and for HCV infection by PCR and by serological assays. Antibody reactivity against GBV-C/HGV was detected in 20.8% (n = 32) and viremia was found in 6.5% (n = 10) of the patients. In no case were viremia and GBV-C/HGV antibodies detected in parallel. HCV infection was observed in 15.6% (n = 24) by RT-PCR. In 20 of these patients, HCV antibodies were detected by enzyme immuno assay (EIA) and immunoblot assay. However, four of the HCV PCR-positive patients were negative by both serological tests. Only two patients were viremic for GBV-C/HGV and HCV in parallel. It is concluded that antibody reactivity against GBV-C/HGV is common among patients on maintenance hemodialysis. In contrast to HCV, parallel occurrence of GBV-C/HGV viremia and GBV-C/HGV seroreactivity was not observed. This suggests that GBV-C/HGV infection might be self-limiting.

show abstract

“…Since this test does not detect current GBV-C infections, our data are likely to underestimate the true frequency of exposure to the virus. However, it is wellknown that the number of anti-E2 reactive sera is several times greater than that of sera positive for GBV-C RNA as determined by RT-PCR [12] and, therefore, the assay for GBV-C antibodies is particularly suitable for epidemiological surveys.…”

Section: Discussionmentioning

confidence: 99%

Antibodies to the E2 Protein of GB Virus C/Hepatitis G Virus: Prevalence and Risk Factors in Different Populations in Italy

et al. 2001

View full text Add to dashboard Cite

GBV-C infections are widespread in the general population in Italy and particularly common in risk groups. The different prevalence of GBV-C antibodies detected in third world immigrants is likely to reflect the prevalence in the countries of origin. However, the observation that the length of residency in Italy is a significant risk factor may suggest that at least some GBV-C infections are contracted in Italy.

show abstract

Immunoassays to study prevalence of antibody against GB virus C in blood donors

Cited by 20 publications

References 35 publications

Antibodies against the GB virus C envelope 2 protein before liver transplantation protect against GB virus Cde novo infection

Antibodies against the GB virus C envelope 2 protein before liver transplantation protect against GB virus Cde novo infection

GB virus C/hepatitis G virus infection in hemodialysis patients: Determination of seroprevalence by a four-antigen recombinant immunoblot assay

Antibodies to the E2 Protein of GB Virus C/Hepatitis G Virus: Prevalence and Risk Factors in Different Populations in Italy

Contact Info

Product

Resources

About